The activity of S9788, recently synthetized as a modulator of multidrug resistance (MDR), was compared with verapamil and cyclosporine A in normal sensitive and MDR K562 cell lines, then in samples from 33 patients with hematological malignancies, using flow cytometry with simultaneous detection of P-glycoprotein and determination of intracellular daunorubicin fluorescence. This technique was compared and correlated with a tritiated daunorubicin accumulation method. In K562 cell lines, S9788 exhibited a significantly higher reversing activity than verapamil and cyclosporine A, and allowed a complete restoration of the accumulation of daunorubicin when used at 5 pmol/L. In the clinical samples, ULTIDRUG RESISTANCE (MDR) of tumor cells is known to be responsible for treatment failures in cancer chemotherapy.',' Overproduction of a transmembrane glycoprotein, called P-glycoprotein, was found to correlate with the development of resistance phenotypes to a number of unrelated drugs, including anthracyclines, epipodophyllotoxins, vinca alkaloids, actinomycin D, and taxoid derivatives. Because of the good activity of anthracycline-based chemotherapy in the treatment of leukemias, the detection of resistant cells in human tumor samples is of great importance to prevent treatment failures when changing therapeutic protocols. Two different approaches could thus be proposed: either discard any MDR-related drug from the chemotherapeutic regimen, or add some compounds able to reverse the resistance phenotype. Since MDR-related drugs are major active therapeutic agents, many groups have focused on the circumvention of the phenomenon using MDRreversing drugs that belong to various therapeutic groups, 0006-4971/94/8401-0006$3.00/0 262 the three compounds were evaluated at equimolar concentration (5 pmol/L) using concomitant exposure to daunorubicin and to the reversing agent. In P-glycoprotein-negative samples, no significant effect on intracellular daunorubicin fluorescence of any of the reversing agents was noted. In the 15 P-glycoprotein-positive samples, a significant increase in daunorubicin fluorescence, by at least one reversing agent, was seen in 10 cases, among which S9788 reversing activity was higher than that of the two other agents in seven cases.
the three compounds were evaluated at equimolar concentration (5 pmol/L) using concomitant exposure to daunorubicin and to the reversing agent. In P-glycoprotein-negative samples, no significant effect on intracellular daunorubicin fluorescence of any of the reversing agents was noted. In the 15 P-glycoprotein-positive samples, a significant increase in daunorubicin fluorescence, by at least one reversing agent, was seen in 10 cases, among which S9788 reversing activity was higher than that of the two other agents in seven cases. Complete reversal was only achieved in one case with S9788. 0 1994 by The American Society of Hematology.
including calcium channel blockers like verapamil, diltiazem, or ni~ardipidine,~.~ calmodulin inhibitors like quinine, quinidine, or reserpine,' and other molecules such as cyclosporine Ah or new cyclosporine derivative^.^ Although, in vitro and in vivo preclinical studies have yielded encouraging results, the clinical reversal of resistance by most of these compounds has been impaired, mainly because of the suprapharmacological concentration levels needed to achieve significant reversal of resistance' and due to the toxic side effects that occur when high doses of the reversing compounds are used. Based on structure-activity relationships' demonstrating that all of the reversing compounds had in common some structural characteristics (two planar aromatic cycles, one tertiary amine base positively charged at physiological pH, and a high degree of lipophilicity), new molecules, including the new aminopiperidine derivative S9788, were recently developed to overcome this problem and reverse P-glycoprotein-mediated MDR phenotypes with a better activity to side effect ratio. S9788 proved to be efficient in several experimental models, in vitro and in phase I study."
The present study was designed to evaluate the potential reversing activity of S9788 in human leukemic cells and compare it with that of verapamil and cyclosporine A, which are considered to be efficient, standard reversing agents. First, flow cytometry analysis of intracellular daunorubicin fluorescence was evaluated and compared with tritiated daunorubicin accumulation. Experiments were then performed using flow cytometry in P-glycoprotein-expressing bone marrow or blood samples from patients with hematological malignancies before any treatment course was determined.
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MATERIALS AND METHODS

Materials and chemicals.
Cell culture materials were from Falcon (Becton Dickinson, Meylan, France). Culture media and additives were purchased from Gibco (Cergy-Pontoise, France), except for fetal calf serum, which was from Costar (Dutscher, Brumath, France). Daunorubicin (Cerubidine; Laboratoire Roger Bellon, Neuilly, France) and verapamil (Isoptine; Laboratoire Biosedra, Malakoff, France) were diluted in physiological saline. Cyclosporine For personal use only. on October 3, 2017. by guest www.bloodjournal.org From France) after dilution of 500 pL of the sample in 10 mL of Ready-S o h scintillation cocktail (Beckman). Experiments were repeated three times and the results were expressed as mean ratios of daunorubicin incorporation (resistanthensitive).
Flow cytometry. Double-labeling flow cytometry analyses of MDR were performed on cell suspensions (cell lines or blast cells from patients) containing lo6 cells/mL using an Orthocyte flow cytometer (Ortho Diagnostic Systems, Roissy, France) according to a methodology described previously." Briefly, intracellular daunorubicin accumulation was assayed by incubating the cells with 2 ymoll L daunorubicin for 2 hours at 37°C. This incubation duration was selected because loading of K562-DXR cells with daunorubicin has reached a plateau by this time (data not shown) and the difference between resistant and parental cells was significant. P-glycoprotein was subsequently labeled using MRK16 monoclonal antibody at a final concentration of 10 pg/mL coupled to fluorescein isothiocyanate-conjugated goat antimouse IgG serum (Sigma) for 30 minutes at 4°C (MRK16-FITC labeling). Membrane-altered cells were identified by incubating the cells in 75 pmol/L propidium iodide for 10 minutes at 4"C, and was not further considered as any membrane alteration could induce some defects in the accumulation of daunorubicin, which could be misattributed to MDR phenotype.
To monitor the two red fluorescence signals of daunorubicin and propidium iodide, a logarithmic amplification was used. The values obtained from histograms analysis were then converted in linear relative fluorescence intensities using the equation: F = 10""X*C' , where F = relative fluorescence intensity, M = number of modules of the amplifier (= 3 for the Orthocyte flow cytometer), N = number of detection channels (= 256 for the Orthocyte flow cytometer), and AC = the difference in the median red fluorescence channel numbers of the two populations being compared. Each analysis was performed in triplicate on at least 5,000 cells, and the results are expressed as the mean ? SD.
From the results obtained with the cell lines, experiments were designed to compare the respective activities of the three compounds in P-glycoprotein-expressing samples from patients with hematological malignancies. The atypic cell population was selected from double light-scattering analysis (forward angle and right angle light scattering). No empirical threshold was considered for P-glycoprotein positivity, but the detection limit was defined for the cell lines. Statistical analyses were performed using Student's t-test to compare the mean relative fluorescence intensity obtained with each experimental series. (Sandimmun; Laboratoire Sandoz, Rueil-Malmaison, France) was solubilized then diluted in physiological saline. S9788 (Fig 1) was obtained from Laboratoire Servier (Courbevoie, France) as a bismethane sulfonate salt and was diluted in 5% glucose solution.
Tritiated daunorubicin was purchased from New England Nuclear (Les Ulis, France) with a specific activity of 122 GBqImmol. MRK-16, anti-P-glycoprotein monoclonal antibody was a kind gift of Dr T. Tsuruo. All other chemicals were purchased from Sigma (St Quentin Fallavier, France).
Cell lines. K562 human leukemic cell line and its subline K562-DXR, selected for its resistance to doxorubicin, were provided by Professor B. Desoize, Institut Jean Godinot, Reims, France. Both cell lines were cultured in RPM1 1640 medium supplemented with 10% heat-inactivated fetal calf serum in a 3 7 T , 5% CO2 atmosphere. The resistant subline, K562-DXR, was maintained in 2 pmoVL doxorubicin-containing medium, and was found to be 185-fold resistant to doxorubicin." Using clonogenic assays, we found that the K562-DXR cell line was 165-fold resistant to daunorubicin (data not shown).
Clinical samples from patients with hematologic malignancies. Twenty-nine fresh bone marrow and four blood samples were analyzed from 33 patients (16 males, 17 females; median age, 56 years, range, 17 to 90) with hematologic malignancies (30 acute leukemias, one leukemic lymphoma, and two acute myelodysplastic syndromes) at diagnosis before any treatment protocol was determined. The leukemic lymphoma and the two acute myelodysplastic syndromes were included in this series because they were treated as acute lymphoblastic and myeloid leukemias. Each sample was obtained during routine cytology sample collection. Bone marrow or blood samples were layered onto Histopaque (Sigma) and centrifuged at 1,500g for 10 minutes at 4°C. The leukocyte fraction was collected by aspiration and resuspended in phenol red-free. RPMI 1640 medium. When the original sample contained less than 50% atypic blast cells, this fraction was cytologically recontrolled using the MayGriinwald-Giemsa staining procedure and characterized before being analyzed for MDR.
Incorporation of 3H-daunorubicin. As previously reported,14 resistance of cells can be assessed by monitoring their accumulation of 'H-daunorubicin. Cell suspensions containing lo5 cells/mL were incubated in 2 pmoVL tritiated daunorubicin solution for 2 hours at 37°C. After being washed twice with cold RPMI 1640 medium, the cells were centrifuged at 800g for 5 minutes and the pellet was left overnight to solubilize in 1 moVL NaOH (1 mL) at 60°C.'5 The solution was then neutralized by glacial acetic acid, and total radioactivity was determined using an LS1800 counter (Beckman, Gagny,
RESULTS
Characterization of the K562 cell lines. Total daunorubicin accumulation was calculated as 14.5 and 4.9 nmoV104 cells, respectively, for sensitive and MDR K562 cell lines, thus indicating a ratio (resistadsensitive) of 0.34. Double-labeling flow cytometry analysis of normal sensitive K562 and MDR K562-DXR cells allowed easy distinction of both cell types (Fig 2) . The labeling rates by MRK16-FITC antibody recognizing P-glycoprotein (green fluorescence) were 82% 2 12% (mean -+ SD, n = 3) for the K562-DXR cells versus 1.6% 2 0.2% for the parental K562 cells. The background noise for MRK16-FITC labeling was calculated from the mean fluorescence value of nonspecific labeling observed by incubating the cells with FITC-conjugated IgG, but without MRK16 monoclonal antibody. Falsepositivity was found to represent 1.2% -C 0.1% of the total cell population. The limit of sensitivity of this method for the detection of P-glycoprotein-expressing cells was estimated for a signal to background noise ratio of 2 and set Red fluorescence (arbitrary units) to 2.5%. However, the KS62-DXR cells accumulated less daunorubicin (red fluorescence) than the parental K562 cells, with a relative fluorescence ratio (resistantkensitive) of 0.37, which is close to the value observed with the 'H-daunorubicin accumulation experiments. Membrane-altered cells were easily identified by the propidium iodide staining, which generated a more intense red fluorescence than daunorubicin.
Activir?, of the reversing agents in the K562-DXR cell line. The activities of the three reversing agents (S9788, verapamil, and cyclosporine A) were evaluated from flow cytometry red fluorescence histograms (Fig 3) and were compared with the results from 'H-daunorubicin accumulation assays ( Table l) . In the K562-DXR cell line, S9788 exhibited a significant reversing activity at 2 and S pmol/L when the cells were incubated simultaneously with daunorubicin and the reversing agent (Table I) , either by 'H-daunorubicin accumulation experiments (P < .Ol) or by flow cytometry analyses (P < .OOl). Cyclosporine A and verapamil induced no significant reversal at 2 pmolk (P > .OS), but did so at S pmol/L, either by 'H-daunorubicin accumulation experiments (P < .OOl and P < .OS, respectively for cyclosporine A and verapamil) or by flow cytometry analyses (P < .01 and P < .OS, respectively for cyclosporine A and verapamil). When reversing activity was found for S9788, cyclosporine A, and verapamil at S pmol/L, both S9788 and cyclosporine A showed significantly higher activity than verapamil (P < .OOl and P < .01, respectively).
Flow cytometry analyses showed that the reversing activity of S9788 was significantly higher than that of cyclosporine A (P < .01). 'H-daunorubicin accumulation assays did not confirm this difference in activity between the two compounds (P > .OS), probably because of larger interexperimental variations.
Complete reversal. ie, comparable daunorubicin accumulation as in the parental sensitive cell line, was significantly achieved with both S9788 and cyclosporine A at S pmol/L and tended to appear with S9788 at 2 pmol/L in 'H-daunorubicin accumulation experiments.
In all cases, the results calculated from the two techniques were found to correlate (R' = .914) as illustrated in Fig 4. Cytologic charcrcterization of the clinical samples. Among 33 samples analyzed. eight contained more than 8S% atypic blast cells at sampling and were not recontrolled after Histopaque; 23 contained SO% to 8S% atypic blast cells "T 
3H-Daunorubicin accumulation ratio
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From A statistically significant difference ( P = .006) in daunorubicin fluorescence was found between P-glycoproteinpositive and -negative samples, with respective median channel numbers for red fluorescence of 29 i 1 1 (n = 15) and 47 2 20 (n = 18), thus corresponding to a relative fluorescence ratio (resistantkensitive) of 0.61. This value differed from the ratio observed in the K562 cell lines (0.37) and demonstrated that the level of resistance found in clinical samples was quite lower than that observed in cell lines selected by exposure to high concentrations of drugs.
Activity of reversing agents in clinical samples. From the results achieved in the K562 cell lines, the three compounds were evaluated at equimolar concentrations (5 pmol/ L) in the clinical samples with concomitant exposure to daunorubicin and to the reversing agent. Because no repetitive sampling was achievable within the same patient, the limit of significance for the variation in daunorubicin fluorescence was set to 12%, corresponding to four-channel variation of the median of the red fluorescence histogram, which was the mean variation observed in repetitive analyses of the same sample (intraexperimental variation).
S9788 was evaluated in all samples. According to the number of cells available for analysis, S9788 was compared with both verapamil and cyclosporine A (12 cases), verapamil only (20 cases), or cyclosporine A only ( I case).
In the 18 P-glycoprotein-negative samples (17 acute leukemias, 1 myelodysplastic syndrome), no significant effect of any reversing agent on daunorubicin fluorescence was observed. Only one sample was found to be borderline, with a 12% increase in daunorubicin fluorescence.
Within the 15 P-glycoprotein-positive samples (Table 3) , 13 Values in bold are the 10 cases in which significant reversal was Abbreviations: NS, nonsignificant; ND, not determined.
achieved by at least one reversing agent. significant increases in daunorubicin fluorescence, by at least one reversing agent, were seen in 10 cases (67%). No relation was found between the rate of MRK16-FITC-labeling and the occurrence resistance reversion with 34% t-23% (mean i SD, n = 10) MRK16-FITC-labeled cells versus 22 ? 1 I (n = 5 ) reversible and nonreversible samples, respectively.
S9788 induced an increase in daunorubicin fluorescence of 24% i 19% (mean ? SD, n = 9), verapamil of 22% i 7% (n = 4), and cyclosporine A of 29% t 13% (n = 3). No statistically significant variation was observed because of the large disparity of the results (12% to 64%, 12% to 28%, and 18% to 43% for S9788, verapamil, and cyclosporine A, respectively). However, in seven cases of 10, S9788 yielded higher increases in daunorubicin than did the other(s) compound(s) (Fig S) , including one case for verapamil and one case for cyclosporine A; in one case, these two compounds yielded the same reversal.
Considering the P-glycoprotein-negative samples as a reference, the mean relative daunorubicin fluorescence of Pglycoprotein-positive samples shifted from 0.67 ? 0.28 to 0.82 i 0.34 (n = 9), 0.61 5 0.08 to 0.74 2 0.09 (n = 4), and 0.60 i 0.10 to 0.76 t 0.08 (n = 3) for S9788, verapamil and cyclosporine A, respectively. The only case of complete reversal of resistance was achieved with S9788 (Table 3 , patient no. 15) , in which the relative fluorescence ratio shifted from 0.68 to 1 .OO. In the 14 samples in which S9788 was comparable to verapamil, five (36%) led to nonsignificant variations of daunorubicin fluorescence, and seven (50%) showed a higher activity of S9788 and two (14%) of verapamil. Among the eight samples in which S9788 was comparable to cyclosporine A, five (62%) led to nonsignificant variations, and two (25%) showed a higher efficiency of cyclosporine A and one (13%) of S9788.
DISCUSSION
Evaluation of MDR in clinical specimens or biological samples has been attempted in numerous tumor types, and the clinical relevance of P-glycoprotein in malignancies is still under debate." Because the chemotherapeutic protocols that are currently used in these pathologies mainly involve MDR-related drugs, emphasis is often laid on hematological malignancies. The techniques used involved detection of mdr gene"." or P-glycoprotein expression in flow cytometry analyses," and assessment of the uptake of anthracyclines either by fluorimetry** or by using radiolabeled molecules. '4 The procedure of double-labeling flow cytometry analysis that we used'' was particularly interesting, because it allowed the simultaneous determination of the expression of P-glycoprotein as a structural parameter of the MDR phenotype and of the incorporation of daunorubicin as a functional parameter, representing its main advantage as the use of a radiolabeled molecule. The possibility of identification of membrane-altered cells by propidium iodide labeling was also of considerable interest, because it avoided the generation of experimental artifacts.
From a technical point of view, the time of the whole experiment was optimized in controlling the kinetics of load- ing of the KS62-DXR cells, with daunorubicin yielding a plateau of intracellular daunorubicin fluorescence at 30 minutes while the parental, normal sensitive cells further incorporated daunorubicin for 60 minutes. These data were consistent with those recently reported" in an LS178Y mouse T-cell lymphoma cell line being infected by pHa MDRI/A retrovirus and expressing P-glycoprotein. Requirements for using the double-labeling flow cytometry technique were the use of viable (nonfixed) cells and of an anti-P-glycoprotein monoclonal antibody directed against external epitopes of the transmembrane protcin such as MRK16 antibody.'.' Other antibodies, also directed against external epitopes of the Pglycoprotein, such as UIC2'5 or 4E3.I5 could also have been used. Because such antibodies were able to reverse MDR when fixed onto P-glycoprotein." the sequence of labeling. first by daunorubicin and then with anti-P-glycoprotein monoclonal antibody, must be strictly respected. The inverted sequence of labeling would lead to an overestimation of daunorubicin accumulation, since the analysis would be performed in cells whose P-glycoprotein activity is blocked by the monoclonal antibody.
In the present study, the results obtained in the K562 cell lines confirmed the ability of S9788 to reverse MDR. which was previously demonstrated in the MDR P388 cell line."' The lack of activity of S9788 in the normal sensitive KS62 cell line and in the P-glycoprotein-negative samples confirmed that P-glycoprotein should be the main cellular target of S9788, as previously demonstrated by photoaffinity labeling with azidopin.?" S9788 was found to be significantly more potent than verapamil and as active as cyclosporine A. yielding complete reversals of resistance at S pmol/L. This further confirmed the results" demonstrating that the optimal concentration for S9788 was between 1 and S prnolk. Our results concerning the comparison of S9788 with verapamil and cyclosporine A were also consistent with those obtained in a collaborative in vitro evaluation of S9788" in either the MDR MCF7 human breast adenocarcinoma cell line or in a cell model derived from a patient with a breast tumor resistant to anthracycline chemotherapy, and using different techniques such as microspectrofluorimetry, flow cytometry. or cytotoxicity assays in the MDR K562 cell line. On the other hand, in this study, the reversing activity of S9788 was not found to be schedule-dependent, and thus appeared to differ from other results showing that a complete reversal of resistance to vincristine was achieved when S9788 was left in contact with the cells for 24 hours after the drug was removed'x or that its activity was increased when a postincubation period with S9788 alone was used.'" This might be explained by the differences in the durations of the preincubation or postincubation periods used (2 hours in our casei3 versus 24'x or 4 hours2") and by the different other mechanisms of resistance being induced by selection of cells resistant either to vincristine or to doxorubicin that might coexist with the Pglycoprotein-mediated MDR phenotype. Other explanations could be proposed on the basis of fluorescence determination of the cellular accumulation of doxorubicin showing that some MDR-modulating agents, such a s cyclosporine A and S9788, might also act at an extramembrane level. helping to restore the distribution of the cytotoxic drug to its nuclear targets."'The extramembranar site of action could be located at the endosoma12' or mitochondrial level,3' where S9788 was found to accumulate in a protonated form.
The correlation that was observed between the flow cytometry fluoresccnce data and the tritiated daunorubicin accumulation confirmed the reliability of the flow cytometry analyses and allowed us to use it to evaluate the potential activity of S9788 in P-glycoprotein-expressing cells from patients with hematological malignancies. thus representing For personal use only. on October 3, 2017. by guest www.bloodjournal.org From cells with a clinically relevant level of resistance lower than that of MDR cell lines selected by exposure to high concentrations of drugs.
Daunorubicin intracellular fluorescence was analyzed as the end point according to our preliminary results in acute leukemia^'^ demonstrating that this parameter was highly correlated ( P < .01) with clinical responses of adult acute leukemias34 to chemotherapeutic regimens containing MDRrelated drugs. In the present study, P-glycoprotein expression was detected in nearly 50% of the samples, thus confirming data reported by other group^'^-^' where, depending on the method of detection, 46% to 7 1 % of leukemia samples were found to express P-glycoprotein. Using the double-labeling flow cytometry technique allowed us to establish that the expression of P-glycoprotein in the clinical samples was correlated with a significant ( P = .006) decrease in daunorubicin accumulation, in agreement with the data we obtained in the K562 cell lines.
The activity of all three compounds evaluated was found to depend on P-glycoprotein expression, because no significant increase in daunorubicin fluorescence was observed in P-glycoprotein-negative samples. This may not be directly related to the cytotoxic activity, since daunorubicin fluorescence is known to be quenched when it is bound to DNA. However, the activity of at least one of the MDR-modulating agents was only detected in 67% of the positive samples, thus indicating that P-glycoprotein should not be the only parameter responsible for the decrease in intracellular retention of daunorubicin, as previously demonstrated. '8 When increases in daunorubicin fluorescence were observed in the clinical samples, S9788 seemed to be more effective than verapamil and as potent as cyclosporine A. This could further justify the hypothesis about the double site of action of these latter compounds on P-glycoprotein functionality and on intracellular sequestration of daunorubicin in extramembrane compartments, while other compounds, like verapamil, seemed only to act on P-glycoprotein functionality. 30 In addition, the concentration ranges that were found to reverse MDR in the clinical samples are pharmacologically achievable in humans for both cyclosporine A3' and for S9788,40 while they remain suprapharmacological for ~erapamil.~"
The present results achieved in clinical samples expressing P-glycoprotein confirmed the potential usefulness of S9788 in circumventing MDR in hematological malignancies. Further studies should be performed with a longer 4-hour postincubation schedule of S9788, since it has been proposedz9 that such a prolonged exposure to the reversing agent could improve its activity. Furthermore, attention should focus on critical assessment of the biological effects of modulators of P-glycoprotein on normal physiological processes in which P-glycoprotein takes part, as it appears that this protein plays a role in many currently undetermined mechanisms.
